The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 01, 2014
Filed:
Feb. 24, 2012
Angela Wandinger-ness, Albuquerque, NM (US);
Larry Sklar, Albuquerque, NM (US);
Jacob Agola, Albuquerque, NM (US);
Zurab Surviladze, Albuquerque, NM (US);
Jeffrey Aubé, Lawrence, KS (US);
Jennifer Golden, Olathe, KS (US);
Chad E. Schroeder, Lawrence, KS (US);
Denise S. Simpson, Lawrence, KS (US);
Angela Wandinger-Ness, Albuquerque, NM (US);
Larry Sklar, Albuquerque, NM (US);
Jacob Agola, Albuquerque, NM (US);
Zurab Surviladze, Albuquerque, NM (US);
Jeffrey Aubé, Lawrence, KS (US);
Jennifer Golden, Olathe, KS (US);
Chad E. Schroeder, Lawrence, KS (US);
Denise S. Simpson, Lawrence, KS (US);
STC.UNM, Albuquerque, NM (US);
University of Kansas, Lawrence, KS (US);
Abstract
This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.